Aevi Genomic Medicine, Inc. :GNMX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016

Aevi Genomic Medicine, Inc. reports financial results for the quarter ended September 30, 2016.

Analysis

  • Summary numbers: Revenues of USD 0 million, Net Earnings of USD -10.57 million.
  • The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.
  • GNMX-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were up this period to 47.26 million compared to 17.73 million in the same period last year.
  • We consider the company to have a Quick & Able profile as it currently does not have any debt. In comparison, the median level of debt as percent of enterprise value for its peer group is currently 0.45%.
  • Of the 6 chosen peers for the company, only 5 of the stocks have an outstanding debt balance. Companies with no debt include FORR-US.
  • Net income of -10.57 million this period compared to a net income of -11.71 million last period. This is a growth of 9.71% over the previous period. In comparison, the peer group grew at 6.88%

Access our Ratings and Scores for Aevi Genomic Medicine, Inc.

Earnings Growth YOY %
Cash & ST Investments %

Access our Ratings and Scores for Aevi Genomic Medicine, Inc.

Company Profile

Aevi Genomic Medicine, Inc. is a medical technology company, which develops protein therapeutics medical therapies. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The Company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of GNMX-US.